{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:59:23Z","timestamp":1781661563488,"version":"3.54.5"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis\/Medicines for Malaria Venture\/PAMAfrica consortium\/European & Developing Countries Clinical Trials Partnership","award":["RIA2018SD-2306"],"award-info":[{"award-number":["RIA2018SD-2306"]}]},{"name":"Novartis\/Medicines for Malaria Venture\/PAMAfrica consortium\/European & Developing Countries Clinical Trials Partnership","award":["RIA2018SD-2306"],"award-info":[{"award-number":["RIA2018SD-2306"]}]},{"name":"Novartis\/Medicines for Malaria Venture\/PAMAfrica consortium\/European & Developing Countries Clinical Trials Partnership","award":["RIA2018SD-2306"],"award-info":[{"award-number":["RIA2018SD-2306"]}]},{"name":"Novartis\/Medicines for Malaria Venture\/PAMAfrica consortium\/European & Developing Countries Clinical Trials Partnership","award":["RIA2018SD-2306"],"award-info":[{"award-number":["RIA2018SD-2306"]}]},{"name":"Novartis\/Medicines for Malaria Venture\/PAMAfrica consortium\/European & Developing Countries Clinical Trials Partnership","award":["RIA2018SD-2306"],"award-info":[{"award-number":["RIA2018SD-2306"]}]},{"name":"Novartis\/Medicines for Malaria Venture\/PAMAfrica consortium\/European & Developing Countries Clinical Trials Partnership","award":["RIA2018SD-2306"],"award-info":[{"award-number":["RIA2018SD-2306"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trop Med Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Evidence-based recommendations for malaria treatment in patients weighing\u2009&lt;\u20095\u00a0kg are lacking as a consequence of differences in pharmacokinetics due to age and\/or body weight (BW), and recruitment challenges in conducting trials in this population. A physiologically based pharmacokinetic (PBPK) model was developed and validated to predict artemether and lumefantrine concentrations in patients\u2009&lt;\u20095\u00a0kg BW aged 1\u201328\u00a0days. The model predictions supplemented data from a trial (CALINA; NCT04300309) with an optimized dose of artemether\u2013lumefantrine (5\u00a0mg artemether: 60\u00a0mg lumefantrine) in patients\u2009&lt;\u20095\u00a0kg with <jats:italic>Plasmodium falciparum<\/jats:italic> malaria.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>PBPK models of artemether and lumefantrine were developed using Simcyp (Version 22) and validation was performed using historical data from adults and paediatric patients. To compare model-predicted and observed values, populations were matched to clinical trial populations (ranging from adults to infants) for patient numbers and demographics. The models were applied to predict artemether maximal concentration (C<jats:sub>max<\/jats:sub>) and lumefantrine C<jats:sub>max<\/jats:sub> and Day 7 concentration (C<jats:sub>168h<\/jats:sub>) in neonates of\u2009&lt;\u20095\u00a0kg BW aged 1\u201328\u00a0days, and for subgroups aged 1\u20137, 8\u201314, and 15\u201328\u00a0days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Validated models for artemether and lumefantrine were used to predict plasma concentrations in neonates and young infants with BW\u2009&lt;\u20095\u00a0kg after 3-day administration of 5\u00a0mg artemether and 60\u00a0mg lumefantrine twice daily with high confidence. The PBPK model using Upreti hepatic cytochrome P450 (CYP)3A4 ontogeny predicted observed artemether and lumefantrine exposure in infants and neonates better than Salem ontogeny. The predicted variability in neonates was comparable to or larger than the variability of observed concentrations in infants and older neonates in the CALINA study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Based on the success of the PBPK models for artemether and lumefantrine in predicting drug concentrations in adults and children, including neonates, modelling and simulation results can be used with confidence to supplement the limited available data for neonates (1\u201328\u00a0days old)\u2009&lt;\u20095\u00a0kg BW obtained from the CALINA study for this rarer and more difficult to recruit patient population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41182-025-00790-w","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T09:00:57Z","timestamp":1756112457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Physiologically based pharmacokinetic modelling to predict artemether and lumefantrine exposure in neonates weighing less than 5\u00a0kg treated with artemether\u2013lumefantrine to supplement the clinical data from the CALINA study"],"prefix":"10.1186","volume":"53","author":[{"given":"Helen","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Abla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay Kumar","family":"Venishetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Schoeberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Zack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Einolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"10381","key":"790_CR1","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S0140-6736(22)02535-1","volume":"401","author":"M Madanitsa","year":"2023","unstructured":"Madanitsa M, Barsosio HC, Minja DTR, Mtove G, Kavishe RA, Dodd J, et al. Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial. Lancet. 2023;401(10381):1020\u201336.","journal-title":"Lancet"},{"issue":"1","key":"790_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12936-020-03373-8","volume":"19","author":"C Danwang","year":"2020","unstructured":"Danwang C, Bigna JJ, Nzalie RNT, Robert A. Epidemiology of clinical congenital and neonatal malaria in endemic settings: a systematic review and meta-analysis. Malar J. 2020;19(1):312.","journal-title":"Malar J"},{"key":"790_CR3","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/S0140-6736(23)01249-7","volume":"402","author":"JR Poespoprodjo","year":"2023","unstructured":"Poespoprodjo JR, Douglas NM, Ansong D, Kho S, Anstey NM. Malaria. Lancet. 2023;402:2328\u201345.","journal-title":"Lancet"},{"issue":"7","key":"790_CR4","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3201\/eid2107.142036","volume":"21","author":"SJ Ceesay","year":"2015","unstructured":"Ceesay SJ, Koivogui L, Nahum A, Abdoulie Taal M, Okebe J, Affara M, et al. Malaria prevalence among young infants in different transmission settings. Africa Emerging Infect Dis. 2015;21(7):1114\u201321.","journal-title":"Africa Emerging Infect Dis"},{"issue":"002","key":"790_CR5","first-page":"1","volume":"1","author":"EPK Ameade","year":"2018","unstructured":"Ameade EPK, Tee CG, Dakurah HC, Opata HM. Uncomplicated malaria in children under 6 months or less than 5 Kg; how prescribers in Ghana manage it in the absence of a national policy. Int J Trop Dis. 2018;1(002):1\u20139.","journal-title":"Int J Trop Dis"},{"issue":"6","key":"790_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3347\/kjp.2014.52.6.639","volume":"52","author":"LE Fitri","year":"2014","unstructured":"Fitri LE, Jahja NE, Huwae IR, Nara MB, Berens-Riha N. Congenital malaria in newborns selected for low birth-weight, anemia, and other possible symptoms in Maumere, Indonesia. Korean J Parasitol. 2014;52(6):639\u201344.","journal-title":"Korean J Parasitol"},{"key":"790_CR7","volume-title":"World Malaria Report 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. World Malaria Report 2023. Geneva: World Health Organization; 2023."},{"key":"790_CR8","volume-title":"Guidelines for the treatment of malaria","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.","edition":"3"},{"key":"790_CR9","unstructured":"The CALINA study group. Pharmacokinetics, safety, and efficacy of an optimized dose of artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in neonates and infants: a multicenter, open-label, single arm Phase 2\/3 study (CALINA). Submitted to Trop Med Health."},{"issue":"15","key":"790_CR10","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1080\/14656566.2022.2130687","volume":"23","author":"LC Kalkman","year":"2022","unstructured":"Kalkman LC, Hanscheid T, Krishna S. Antimalarial treatment in infants. Expert Opin Pharmacother. 2022;23(15):1711\u201326.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"790_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123283","volume":"10","author":"MK Mbonye","year":"2015","unstructured":"Mbonye MK, Burnett SM, Naikoba S, Zawedde-Muyanja S, Kinoti SN, Ronald A, et al. Malaria care in infants aged under six months in Uganda: an area of unmet needs. PLoS ONE. 2015;10(4): e0123283.","journal-title":"PLoS ONE"},{"issue":"2","key":"790_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/tropej\/fms069","volume":"59","author":"MJ Alao","year":"2013","unstructured":"Alao MJ, Gbado\u00e9 AD, Meremikwu M. Plasmodium falciparum malaria in infants under 5kg: retrospective surveillance of hospital records in five sub-Saharan African countries. J Trop Pediatr. 2013;59(2):154\u20139.","journal-title":"J Trop Pediatr"},{"key":"790_CR13","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(08)61492-0","volume":"372","author":"S Abdulla","year":"2008","unstructured":"Abdulla S, Sagara I, Borrmann S, D\u2019Alessandro U, Gonzalez R, Hamel M, et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet. 2008;372:1819\u201327.","journal-title":"Lancet"},{"issue":"9","key":"790_CR14","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1128\/AAC.01115-10","volume":"55","author":"AA Djimd\u00e9","year":"2011","unstructured":"Djimd\u00e9 AA, Tekete M, Abdulla S, Lyimo J, Bassat Q, Mandomando I, Lef\u00e8vre G, Borrmann S. B2303 Study Group Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2011;55(9):3994.","journal-title":"Antimicrob Agents Chemother"},{"key":"790_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12936-015-0682-7","volume":"14","author":"AB Tiono","year":"2015","unstructured":"Tiono AB, Tinto H, Alao MJ, Meremikwu M, Tshefu A, Ogutu B, et al. Increased systemic exposures of artemether and dihydroartemisinin in infants under 5kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem\u00ae). Malar J. 2015;14:157.","journal-title":"Malar J"},{"issue":"10","key":"790_CR16","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.xphs.2016.06.026","volume":"105","author":"W Lin","year":"2016","unstructured":"Lin W, Heimbach T, Jain JP, Awasthi R, Hamed K, Sunkara G, He H. A physiologically based pharmacokinetic model to describe artemether pharmacokinetics in adult and pediatric patients. J Pharm Sci. 2016;105(10):3205\u201313.","journal-title":"J Pharm Sci"},{"issue":"6","key":"790_CR17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00044011-199918060-00006","volume":"18","author":"G Lef\u00e8vre","year":"1999","unstructured":"Lef\u00e8vre G, Thomsen MS. Understanding the pharmacokinetics of Coartem\u00ae. Clin Drug Invest. 1999;18(6):467\u201380.","journal-title":"Clin Drug Invest"},{"issue":"6","key":"790_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1046\/j.1365-2125.1998.00830.x","volume":"46","author":"F Ezzet","year":"1998","unstructured":"Ezzet F, Mull R, Karbwang J. Population pharmacokinetics and therapeutics response of CGP 56697 (artemether \u2013 benflumetol) in malaria patients. Br J Clin Pharmacol. 1998;46(6):553\u201361.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"790_CR19","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/infdis\/jiw338","volume":"214","author":"E Tchaparian","year":"2016","unstructured":"Tchaparian E, Sambol NC, Arinaitwe E, et al. Population pharmacokinetics and pharmacodynamics of lumefantrine in young Ugandan children treated with artemether-lumefantrine for uncomplicated malaria. J Infect Dis. 2016;214(8):1243\u201351.","journal-title":"J Infect Dis"},{"issue":"1","key":"790_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/psp4.12479","volume":"9","author":"C Kuemmel","year":"2020","unstructured":"Kuemmel C, Yang Y, Zhang X, et al. Consideration of a credibility assessment framework in model-informed drug development: potential application to physiologically-based pharmacokinetic modeling and simulation. CPT Pharmacometrics Syst Pharmacol. 2020;9(1):21\u20138.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"790_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cpt.37","volume":"97","author":"HM Jones","year":"2015","unstructured":"Jones HM, Chen Y, Gibson C, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247\u201362.","journal-title":"Clin Pharmacol Ther"},{"key":"790_CR22","first-page":"2697","volume":"13","author":"S Khalid","year":"2023","unstructured":"Khalid S, Rasool MF, Masood I, et al. Application of a physiologically based pharmacokinetic model in predicting captopril disposition in children with chronic kidney disease. Nat Sci Rep. 2023;13:2697.","journal-title":"Nat Sci Rep"},{"key":"790_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/psp4.12101","volume":"5","author":"W Zhou","year":"2016","unstructured":"Zhou W, Johnson TN, Xu H, et al. Predictive performance of physiologically based pharmacokinetic and population pharmacokinetic modeling of renally cleared drugs in children. CPT Pharmacometrics Syst Pharmacol. 2016;5:475\u201383.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"790_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1475-2875-8-S1-S7","volume":"8","author":"S Abdulla","year":"2009","unstructured":"Abdulla S, Sagara I. Dispersible formulation of artemether\/lumefantrine: specifically developed for infants and young children. Malar J. 2009;8(1):7.","journal-title":"Malar J"},{"key":"790_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/1475-2875-11-303","volume":"11","author":"S Zaloumis","year":"2012","unstructured":"Zaloumis S, Humberstone A, Charman SA, et al. Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malar J. 2012;11:303.","journal-title":"Malar J"},{"issue":"1","key":"790_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0928-0987(99)00037-8","volume":"9","author":"D Colussi","year":"1999","unstructured":"Colussi D, Parisot C, Legay F, et al. Binding of artemether and lumefantrine to plasma proteins and erythrocytes. Eur J Pharm Sci. 1999;9(1):9\u201316.","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"790_CR27","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1128\/AAC.05136-11","volume":"55","author":"S Salman","year":"2011","unstructured":"Salman S, Page-Sharp M, Griffin S, et al. Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother. 2011;55(11):5306\u201313.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"790_CR28","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1046\/j.1365-2125.2002.01696.x","volume":"54","author":"G Lef\u00e8vre","year":"2002","unstructured":"Lef\u00e8vre G, Carpenter P, Souppart C, Schmidli H, McClean M, Stypinski D. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol. 2002;54(5):485\u201392.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"790_CR29","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1124\/dmd.111.040352","volume":"39","author":"M Honda","year":"2011","unstructured":"Honda M, Muroi Y, Tamaki Y, et al. Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether. Drug Metab Dispos. 2011;39(10):1860\u20135.","journal-title":"Drug Metab Dispos"},{"key":"790_CR30","doi-asserted-by":"crossref","unstructured":"Djimd\u00e9 AA, Lef\u00e8vre G. Understanding the pharmacokinetics of Coartem\u00ae Malaria J 2009; 8(Suppl 1):S4.","DOI":"10.1186\/1475-2875-8-S1-S4"},{"issue":"3","key":"790_CR31","first-page":"209","volume":"42","author":"OA Kotila","year":"2013","unstructured":"Kotila OA, Olaniyi OO, Adegoke AO, et al. Experimental determination of the physicochemical properties of lumefantrine. Afr J Med Med Sci. 2013;42(3):209\u201314.","journal-title":"Afr J Med Med Sci"},{"issue":"2","key":"790_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","volume":"37","author":"NJ White","year":"1999","unstructured":"White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet. 1999;37(2):105\u201325.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"790_CR33","first-page":"434","volume":"15","author":"S Borrmann","year":"2010","unstructured":"Borrmann S, Sallas WM, Machevo S, et al. The effect of food consumption on lumefantrine bioavailability in African children receiving artemether\u2013lumefantrine crushed or dispersible tablets (Coartem\u00ae) for acute uncomplicated Plasmodium falciparum malaria. Trop Med Int Health. 2010;15(4):434\u201341.","journal-title":"Trop Med Int Health"},{"issue":"10","key":"790_CR34","first-page":"e00518","volume":"62","author":"DL Lohy","year":"2018","unstructured":"Lohy DL, Rulisa S, de Vries PJ, et al. Population pharmacokinetics of artemether, dihydroartemisinin, and lumefantrine in Rwandese pregnant women treated for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2018;62(10):e00518-e618.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"790_CR35","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/QAI.0b013e3181acb4ff","volume":"51","author":"P German","year":"2009","unstructured":"German P, Parikh S, Lawrence J, et al. Lopinavir\/ritonavir affects pharmacokinetic exposure of artemether\/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr. 2009;51(4):424\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"790_CR36","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40262-014-0140-7","volume":"53","author":"F Salem","year":"2014","unstructured":"Salem F, Johnson TN, Abduljalil K, et al. A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. Clin Pharmacokinet. 2014;53(7):625\u201336.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"790_CR37","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/jcph.585","volume":"56","author":"VV Upreti","year":"2016","unstructured":"Upreti VV, Wahlstrom JL. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2016;56(3):266\u201383.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"790_CR38","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1124\/dmd.123.001270","volume":"51","author":"TN Johnson","year":"2023","unstructured":"Johnson TN, Howgate EM, de Wildt SN, et al. Use of developmental midazolam and 1-hydroxymidazolam data with pediatric physiologically based modeling to assess cytochrome P450 3A4 and uridine diphosphate glucuronosyl transferase 2B4 ontogeny in vivo. Drug Metab Dispos. 2023;51(8):1035\u201345.","journal-title":"Drug Metab Dispos"},{"key":"790_CR39","unstructured":"Einolf HJ, Gu H, Badee J. Modeling pediatric drug exposure using different hepatic CYP3A4 ontogenies. 2022, Simcyp Consortium Meeting Poster Presentation, Sheffield UK."},{"issue":"9","key":"790_CR40","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/jcph.2452","volume":"64","author":"M Codaccioni","year":"2024","unstructured":"Codaccioni M, Southall RL, Dinh J, Johnson TN. Prediction of pediatric pharmacokinetics for CYP3A4 metabolized drugs: comparison of the performance of two hepatic ontogeny within a physiologically based pharmacokinetic model. J Clin Pharmacol. 2024;64(9):1083\u201394.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"790_CR41","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1046\/j.1365-2125.2001.01370.x","volume":"51","author":"TN Johnson","year":"2001","unstructured":"Johnson TN, Tanner MS, Tucker GT. Enterocytic CYP3A4 in a pediatric population: developmental changes and the effects of celiac disease and cystic fibrosis. Br J Clin Pharmacol. 2001;51(5):451\u201360.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"790_CR42","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.bcp.2009.03.029","volume":"78","author":"EL Croom","year":"2009","unstructured":"Croom EL, Stevens JC, Hines RN, et al. Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem Pharmacol. 2009;78(2):184\u201390.","journal-title":"Biochem Pharmacol"},{"issue":"26","key":"790_CR43","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/S0024-3205(97)01011-4","volume":"61","author":"T Tateishi","year":"1997","unstructured":"Tateishi T, Nakura H, Asoh M, et al. A comparison of hepatic cytochrome P450 protein expression between infancy and post-infancy. Life Sci. 1997;61(26):2567\u201374.","journal-title":"Life Sci"},{"issue":"7","key":"790_CR44","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/dmd.115.067546","volume":"44","author":"RE Pearce","year":"2016","unstructured":"Pearce RE, Gaedigk R, Twist GP, et al. Developmental expression of CYP2B6: a comprehensive analysis of mRNA expression, protein content and bupropion hydroxylase activity and the impact of genetic variation. Drug Metab Dispos. 2016;44(7):948\u201358.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"790_CR45","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1208\/s12248-014-9592-9","volume":"16","author":"K Abduljalil","year":"2014","unstructured":"Abduljalil K, Jamei M, Rostami-Hodjegan A, et al. Changes in individual drug independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model. AAPS J. 2014;16(3):568\u201376.","journal-title":"AAPS J"},{"issue":"1","key":"790_CR46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1517\/14656566.8.1.75","volume":"8","author":"G Kokwaro","year":"2007","unstructured":"Kokwaro G, Mwai L, Nzila A. Artemether\/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother. 2007;8(1):75\u201394.","journal-title":"Expert Opin Pharmacother"},{"key":"790_CR47","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/1475-2875-9-275","volume":"9","author":"S Ali","year":"2010","unstructured":"Ali S, Najmi MH, Tarning J, et al. Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. Malar J. 2010;9:275.","journal-title":"Malar J"},{"key":"790_CR48","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1124\/dmd.30.8.883","volume":"30","author":"JA Williams","year":"2002","unstructured":"Williams JA, Ring BJ, Cantrell VE, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002;30:883\u201391.","journal-title":"Drug Metab Dispos"},{"key":"790_CR49","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1021\/acs.chemrestox.9b00223","volume":"32","author":"MK Matlock","year":"2019","unstructured":"Matlock MK, Tambe A, Elliott-Higgins J, Hines RH, Miller GP, Swamidass SJ. A time embedded network models the ontogeny of 23 hepatic drug metabolizing enzymes. Chem Res Toxicol. 2019;32:1707\u201321.","journal-title":"Chem Res Toxicol"},{"issue":"7","key":"790_CR50","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1124\/dmd.115.068593","volume":"44","author":"NC Sadler","year":"2016","unstructured":"Sadler NC, Nandhikonda P, Webb-Robertson BJ, et al. Hepatic cytochrome P450 activity, abundance, and expression throughout human development. Drug Metab Dispos. 2016;44(7):984\u201391.","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 1","key":"790_CR51","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/0035-9203(94)90469-3","volume":"88","author":"TG Brewer","year":"1994","unstructured":"Brewer TG, Peggins JO, Grate SJ, et al. Neurotoxicity in animals due to arteether and artemether. Trans R Soc Trop Med Hyg. 1994;88(Suppl 1):S33\u20136.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4","key":"790_CR52","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.pt.2008.01.006","volume":"24","author":"N White","year":"2008","unstructured":"White N, Stepniewska K, Barnes K, Price RN, Simpson J. Simplified antimalarial therapeutic monitoring: using the day-7 drug level? Trends Parasitol. 2008;24(4):159\u201363.","journal-title":"Trends Parasitol"},{"key":"790_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0456-7","volume":"13","author":"WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK\/PD Study Group","year":"2015","unstructured":"WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK\/PD Study Group. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med. 2015;13: 227.","journal-title":"BMC Med"},{"key":"790_CR54","unstructured":"Novartis Pharmaceuticals Corporation. Coartem\u00ae Prescribing Information. 2024. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/coartem.pdf. Accessed 8 July 2025."},{"issue":"9","key":"790_CR55","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/psp4.13013","volume":"12","author":"N Abla","year":"2023","unstructured":"Abla N, Howgate E, Rowland-Yeo K, et al. Development and application of a PBPK modeling strategy to support antimalarial drug development. CPT Pharmacometrics Syst Pharmacol. 2023;12(9):1335\u201346.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"27","key":"790_CR56","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/86882","volume":"2001","author":"P Kuehl","year":"2001","unstructured":"Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet. 2001;2001(27):383\u201391.","journal-title":"Nature Genet"},{"issue":"2","key":"790_CR57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5414\/CPP38053","volume":"38","author":"JA Johnson","year":"2000","unstructured":"Johnson JA. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther. 2000;38(2):53\u201360.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"790_CR58","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1124\/jpet.111.189597","volume":"341","author":"M Temesvari","year":"2012","unstructured":"Temesvari M, Kobori L, Paulik J, et al. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. J Pharmacol Exp Ther. 2012;341:294\u2013305.","journal-title":"J Pharmacol Exp Ther"},{"key":"790_CR59","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/PGPM.S379945","volume":"16","author":"KJ Marwa","year":"2023","unstructured":"Marwa KJ, Kapesa A, Kamugisha E, et al. The influence of cytochrome P450 polymorphisms on pharmacokinetic profiles and treatment outcomes among malaria patients in Sub-Saharan Africa: a systematic review. Pharmacogenom Personal Med. 2023;16:449\u201361.","journal-title":"Pharmacogenom Personal Med"},{"key":"790_CR60","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/03602530902843483","volume":"41","author":"SF Zhou","year":"2009","unstructured":"Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41:89\u2013295.","journal-title":"Drug Metab Rev"}],"container-title":["Tropical Medicine and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41182-025-00790-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41182-025-00790-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41182-025-00790-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:45:11Z","timestamp":1757425511000},"score":1,"resource":{"primary":{"URL":"https:\/\/tropmedhealth.biomedcentral.com\/articles\/10.1186\/s41182-025-00790-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["790"],"URL":"https:\/\/doi.org\/10.1186\/s41182-025-00790-w","relation":{},"ISSN":["1349-4147"],"issn-type":[{"value":"1349-4147","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E6 Guidelines for Good Clinical Practice that have their origin in the Declaration of Helsinki. The study protocol was reviewed and approved by the institutional ethics committee or review board for each center and by national health authorities. The study design was also discussed and agreed with SwissMedic, the WHO, and with some malaria-endemic countries via a Marketing Authorisation for Global Health Products consultation. Informed consent was obtained from the legally acceptable representative, i.e. parent or legal guardian, of each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.G., V.K.V., B.S., J.Z., and H.J.E. are employees of Novartis; H.G. and J.Z. are Novartis stockholders. N.A.G. is an employee of Medicines for Malaria Venture.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}